Volume 152, Issue 3, Pages (March 2019)

Slides:

Advertisements

Similar presentations

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

Advertisements

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study Alan M. Nichol,

Volume 144, Issue 1, Pages (January 2017)

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead J. Carlijn Van Gaal, Eveline S.J.M. De Bont, Suzanne.

Amy M. Lin, Charles J. Ryan, Eric J. Small

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

Utilization of second trimester maternal serum screening for down syndrome by advanced maternal age women Peter Benn, James Egan American Journal of.

Volume 148, Issue 1, Pages (January 2018)

Bladder Cancer: Management and Future Directions

Volume 122, Issue 3, Pages (March 2002)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Volume 72, Issue 5, Pages (November 2017)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

Volume 148, Issue 1, Pages (January 2018)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

2016 Curt Stern Award Address: From Rare to Common Diseases: Translating Genetic Discovery to Therapy1 Brendan Lee The American Journal of Human Genetics

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Optimising Hormone Therapy in Advanced Disease

Details and Difficulties Regarding the New Lung Cancer Staging System

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Bisphosphonate exposure and Atypical Femoral Fractures

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 152, Issue 1, Pages (January 2019)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Roy Hertz, M.D. (1909–2002): The cure of choriocarcinoma and its impact on the development of chemotherapy for cancer Jonathan P Yarris, B.S., Alan J.

Volume 143, Issue 2, Pages (November 2016)

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Volume 152, Issue 1, Pages (January 2019)

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Volume 152, Issue 1, Pages (January 2019)

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Jan Roigas European Urology Supplements

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Bone 2014;69C:89 (Fig. 2) Reproduced from Bone, 69C:89-97, Copyright (2014), with permission from Elsevier.

Volume 115, Issue 1, Pages (October 2009)

Lisa A. Beck, MD, Sarbjit Saini, MD

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 152, Issue 3, Pages 540-547 (March 2019) Brachytherapy: A critical component of primary radiation therapy for cervical cancer Christine H. Holschneider, Daniel G. Petereit, Christina Chu, I-Chow Hsu, Yevgeniya J. Ioffe, Ann H. Klopp, Bhavana Pothuri, Lee-may Chen, Catheryn Yashar Gynecologic Oncology Volume 152, Issue 3, Pages 540-547 (March 2019) DOI: 10.1016/j.ygyno.2018.10.016 Copyright © 2018 Elsevier Inc., American Brachytherapy Society Terms and Conditions

Fig. 1 Adjusted overall survival by boost modality (brachytherapy vs. IMRT/SBRT) as corrected for age, Charlson/Deyo comorbidity score, stage, and chemotherapy utilization. (Reprinted from Gill BS, Lin JF, Krivak TC, et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 2014; 90:1083–90; with permission from Elsevier.) Gynecologic Oncology 2019 152, 540-547DOI: (10.1016/j.ygyno.2018.10.016) Copyright © 2018 Elsevier Inc., American Brachytherapy Society Terms and Conditions